Last reviewed · How we verify
Vitamin D (Cholecalciferol )
Vitamin D (Cholecalciferol ) is a Vitamin/Steroid hormone Small molecule drug developed by McGill University Health Centre/Research Institute of the McGill University Health Centre. It is currently FDA-approved for Vitamin D deficiency, Hypocalcemia, Hypoparathyroidism. Also known as: DIN number 00821772, (Cholecalciferol ), osavidin.
Vitamin D (cholecalciferol) is converted in the body to its active form, calcitriol, which regulates calcium and phosphate homeostasis and modulates immune function.
Vitamin D (cholecalciferol) is converted in the body to its active form, calcitriol, which regulates calcium and phosphate homeostasis and modulates immune function. Used for Vitamin D deficiency, Hypocalcemia, Hypoparathyroidism.
At a glance
| Generic name | Vitamin D (Cholecalciferol ) |
|---|---|
| Also known as | DIN number 00821772, (Cholecalciferol ), osavidin |
| Sponsor | McGill University Health Centre/Research Institute of the McGill University Health Centre |
| Drug class | Vitamin/Steroid hormone |
| Target | Vitamin D receptor (VDR) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology, Immunology, Bone Health |
| Phase | FDA-approved |
Mechanism of action
Cholecalciferol is a fat-soluble vitamin that undergoes hydroxylation in the liver to 25-hydroxyvitamin D, then in the kidneys to the active hormone 1,25-dihydroxyvitamin D (calcitriol). Calcitriol binds to the vitamin D receptor (VDR) in target tissues to regulate intestinal calcium absorption, bone mineralization, and immune cell differentiation and function.
Approved indications
- Vitamin D deficiency
- Hypocalcemia
- Hypoparathyroidism
- Osteomalacia
- Rickets
- Osteoporosis prevention and treatment
Common side effects
- Hypercalcemia
- Hypercalciuria
- Nausea
- Vomiting
- Constipation
- Weakness
Key clinical trials
- Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants (PHASE2)
- Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity (PHASE2)
- Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors
- Acute Vitamin D Supplementation on Testosterone in Females (NA)
- Association Between Benign Paroxysmal Positional Vertigo and Vitamin D Deficiency .
- PRESS -PAR: Early Detection and PREvention of Symptomatic postSurgical hypoPARathyroidism After Thyroid Surgery" (NA)
- Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients (PHASE2)
- Effect of the Consumption of Cookies Enriched With Plant Proteins and of a Vitamin D Supplement on the Progression of Sarcopenia in the Elderly (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vitamin D (Cholecalciferol ) CI brief — competitive landscape report
- Vitamin D (Cholecalciferol ) updates RSS · CI watch RSS
- McGill University Health Centre/Research Institute of the McGill University Health Centre portfolio CI
Frequently asked questions about Vitamin D (Cholecalciferol )
What is Vitamin D (Cholecalciferol )?
How does Vitamin D (Cholecalciferol ) work?
What is Vitamin D (Cholecalciferol ) used for?
Who makes Vitamin D (Cholecalciferol )?
Is Vitamin D (Cholecalciferol ) also known as anything else?
What drug class is Vitamin D (Cholecalciferol ) in?
What development phase is Vitamin D (Cholecalciferol ) in?
What are the side effects of Vitamin D (Cholecalciferol )?
What does Vitamin D (Cholecalciferol ) target?
Related
- Drug class: All Vitamin/Steroid hormone drugs
- Target: All drugs targeting Vitamin D receptor (VDR)
- Manufacturer: McGill University Health Centre/Research Institute of the McGill University Health Centre — full pipeline
- Therapeutic area: All drugs in Endocrinology, Immunology, Bone Health
- Indication: Drugs for Vitamin D deficiency
- Indication: Drugs for Hypocalcemia
- Indication: Drugs for Hypoparathyroidism
- Also known as: DIN number 00821772, (Cholecalciferol ), osavidin
- Compare: Vitamin D (Cholecalciferol ) vs similar drugs
- Pricing: Vitamin D (Cholecalciferol ) cost, discount & access